- Home
- XBP vs XGN Comparison
XBP vs XGN Comparison
Compare XBP & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBP | XGN |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | United States |
| Employees | 10998 | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 74.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | XBP | XGN |
|---|---|---|
| Price | $3.93 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.14 |
| AVG Volume (30 Days) | 8.2K | ★ 328.2K |
| Earning Date | 03-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.51 |
| Revenue Next Year | N/A | $13.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $2.75 |
| 52 Week High | $8.55 | $12.23 |
Technical Indicators
Market Signals| Indicator | XBP | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.39 | 29.76 |
| Support Level | $0.62 | N/A |
| Resistance Level | $8.28 | $3.89 |
| Average True Range (ATR) | 0.53 | 0.25 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 14.17 | 7.23 |
Price Performance
Historical ComparisonAbout XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine business process automation and enable digital transformation.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.